Related Experiment Videos
Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function
Gert De Schoenmakere1, Dominique Chauveau, Jean-Pierre Grünfeld
1Service de Néphrologie, Hôpital Necker, Paris, France.
Insights
Enzyme replacement therapy shows promise for Anderson-Fabry disease, stabilizing renal function and improving cardiac structure. This case study highlights potential clinical benefits beyond biochemical markers.
Area of Science:
- Biochemistry
- Cardiology
- Nephrology
Background:
- Enzyme replacement therapy (ERT) has shown biochemical benefits in Anderson-Fabry disease.
- Clinical efficacy, particularly for renal function and cardiac hypertrophy, requires further investigation.
Observation:
- A patient with Anderson-Fabry disease and moderately impaired renal function received ERT.
- The patient's renal function stabilized during enzyme treatment.
- Left ventricular hypertrophy showed a tendency towards regression.
Findings:
- This case represents the first observation of clinical efficacy of ERT in Anderson-Fabry disease patients with moderate renal impairment.
- ERT may offer clinical benefits in managing organ damage associated with the disease.
Implications:
- These findings suggest ERT could be a valuable therapeutic option for Anderson-Fabry disease patients with compromised renal function.
- Further clinical trials are warranted to confirm these observations and establish ERT's role in improving clinical outcomes.
Abstract:
Two recent randomized trials pointed out the beneficial effect of enzyme replacement therapy on biochemical parameters in patients with Anderson-Fabry's disease. Clinical end-points, such as amelioration or stabilization of renal function deterioration, or improvement of left ventricular hypertrophy have not been evaluated in depth. We report the case of a patient whose moderately impaired renal function was stabilized with the start of enzyme treatment. In addition, left ventricular hypertrophy tended to regress. To our knowledge this is the first observation of clinical efficacy of the enzyme replacement therapy in Anderson-Fabry's disease in patients with moderately impaired renal function.